HIMS or Hims & Hers Health, Inc., a popular health and wellness platform, is aiming for strategic international expansion to boost business. A landmark move, it first acquired ZAVA, the European digital health platform, and began operations across Germany, the U.K., France, and Ireland. The conquest didn’t end there. The June 2025 acquisition gives over 1.3 million active users on a platter. This means it also receives approximately 2.3 million consultations conducted by ZAVA’s in-house medical team in 2024. The integration has placed both brands in a powerful position, enabling them to provide personalized, hassle-free healthcare across Europe with ease.
Riding this wave of success, the company has also planned an entry into the Canadian market, at an opportune moment, making a debut with generic semaglutide. This revolutionary treatment for obesity carries an appeal for Canadians who are struggling with obesity issues – that’s nearly two-thirds of the adult population. The eye-catching holistic weight loss modality will be available at a low cost compared to other existing brand options. 24/7 provider support, combined with minimized drug costs and user-friendly digital accessibility, is a hard-to-refuse proposition for the local Canadian population.
Clearly, the growth roadmap for the company is laid out, where organic scaling and strategic acquisitions are not mere potential milestones but ahead-of-time achieved goals. Multilingual provider networks will take the reins alongside localized care delivery, alongside categorically infused treatments for chronic conditions. This way, Him & Hers is successfully transforming into a global digital health leader, moving away from being a U.S.-centric platform.
A Strong Momentum Stock
Personal care is now delivered differently, with healthcare AI companies like HIMS reshaping digital access to healthcare. Since 2017, Hims & Hers Health Inc. has grown steadily, specializing in subscription-based services. Its outreach also involves retail partnerships that bring a wide variety of health needs across critical therapeutic classes. Thus, the company operates with multiple revenue streams, particularly focusing on online subscriptions and retail.
Now, for its stock. HIMS is considered a strong buy, a Zacks Rank #1, and holds a Momentum Style score of B. Its VBM Score is also B. Its shares have fluctuated, but if it was 8.5% down in the past week, they have gained 13.4% over four weeks. And in the last year, the stocks have gained about 134%. The average trading volume was a whopping 33,722,048, with shares exchanged in the previous 20 days.
In June 2025, the company raised $1 billion to accelerate its global expansion plans with AI-driven healthcare. Known for its D-2-C approach, the impressive $1 billion is more than the initial target of $450 million that was set. This only shows steadily growing investor confidence in the company’s long-term vision, breeding the momentum that we are observing today. Andrew Dudum, Founder and CEO, said, “With this capital, we can move faster—growing internationally, expanding personalized care at scale, and investing in AI and data to bring precision care to millions,”.
A Milestone Moment for the Telehealth Leader
The funds raised are the largest ever in Hims & Hers’ history. This underscores the firm’s fruition from a DTC healthcare technology brand into a serious contender in the global digital healthcare space. No doubt, the company has built itself steadily, recognizing the need for primary care, mental health, dermatology, and more, setting foot in the United States first and then expanding abroad.
How will the funds be used?
Strategically, of course. The injected $1billion will speed up international expansion, introducing its branded customer-centric care model to the world market. Moreover, advanced personalized healthcare and precision treatments will be customized to meet individual demands. Diagnosis will be made highly precise as significant investments in AI and data science are made, allowing cutting-edge technology to improve patient outcomes.
People want convenience, discretion, and hands-on support during their healthcare journey. A powerful platform like Hims & Hers will become an essential part in many people’s lives across the digital healthcare landscape.
Bright Days Ahead
The company is undoubtedly ambitious, with milestone funding strategies that are propelling it into the next stage of innovation. The demand for personalized healthcare, which was already booming, will now be prominently recognized as the company lays the groundwork to redefine what modern healthcare looks like.
